Journal of Natural Products 2004-06-01

Metabolomic differentiation of Cannabis sativa cultivars using 1H NMR spectroscopy and principal component analysis.

Young Hae Choi, Hye Kyong Kim, Arno Hazekamp, Cornelis Erkelens, Alfons W M Lefeber, Robert Verpoorte

Index: J. Nat. Prod. 67(6) , 953-7, (2004)

Full Text: HTML

Abstract

The metabolomic analysis of 12 Cannabis sativa cultivars was carried out by 1H NMR spectroscopy and multivariate analysis techniques. Principal component analysis (PCA) of the 1H NMR spectra showed a clear discrimination between those samples by principal component 1 (PC1) and principal component 3 (PC3) in cannabinoid fraction. The loading plot of PC value obtained from all 1)H NMR signals shows that Delta9-tetrahydrocannabinolic acid (THCA) and cannabidiolic acid (CBDA) are important metabolites to differentiate the cultivars from each other. The discrimination of the cultivars could also be obtained from a water extract containing carbohydrates and amino acids. The level of sucrose, glucose, asparagine, and glutamic acid are found to be major discriminating metabolites of these cultivars. This method allows an efficient differentiation between cannabis cultivars without any prepurification steps.


Related Compounds

Related Articles:

[Simultaneous determination of delta-9-tetrahydrocannabinol cannabidiol and cannabinol in edible oil using ultra performance liquid chromatography-tandem mass spectrometry].

2010-11-01

[Se Pu 28(11) , 1015-9, (2010)]

Extended urinary Delta9-tetrahydrocannabinol excretion in chronic cannabis users precludes use as a biomarker of new drug exposure.

2009-11-01

[Drug Alcohol Depend. 105(1-2) , 24-32, (2009)]

Implications of plasma Delta9-tetrahydrocannabinol, 11-hydroxy-THC, and 11-nor-9-carboxy-THC concentrations in chronic cannabis smokers.

2009-10-01

[J. Anal. Toxicol. 33(8) , 469-77, (2009)]

Correlations and agreement between delta-9-tetrahydrocannabinol (THC) in blood plasma and timeline follow-back (TLFB)-assisted self-reported use of cannabis of patients with cannabis use disorder and psychotic illness attending the CapOpus randomized clinical trial.

2012-06-01

[Addiction 107(6) , 1123-31, (2012)]

[Interpretation of blood analysis data found after passive exposure to cannabis].

2010-01-01

[Arch. Kriminol. 225(3-4) , 90-8, (2010)]

More Articles...